NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

February 15, 2023

Study Completion Date

February 15, 2023

Conditions

Ovarian CancerBreast CancerSolid TumorProstate CancerEndometrial Cancer

Interventions

DRUG

CYH33

Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor

Trial Locations (7)

Scientia Cancer Centre, Sydney

Monash Cancer Centre, Melbourne

Integrated Oncology Network PTY LTD, Brisbane

UT Southwestern: Simmons Cancer Center, Dallas

MD Anderson Cancer Center, Houston

Yale Cancer Center, New Haven

Fudan University - Pudong Medical Center, Shanghai